钆布醇、钆特醇与钆特酸葡甲胺在多个身体区域的信号增强及增强动力学:一项对比动物研究
该动物研究将15只健康雄性新西兰白兔随机分为3组,分别静脉注射0.1 mmol/kg体重的钆布醇、钆特醇或钆特酸葡甲胺,在1.5 T MR上采集多期T1加权图像并测定脑、舌、下颌下腺、肝、脾、前列腺、肌肉及血液/主动脉的信号增强,注射后30分钟处死动物用ICP-OES测定组织钆浓度。结果显示三种对比剂的信号增强时间过程相似,钆布醇的信号增强幅度在除脑以外的所有组织中均更高(P<0.05),钆特醇与钆特酸葡甲胺之间无显著差异,组织钆浓度无差异,信号增强与钆浓度呈线性相关,钆布醇的单位钆浓度增强效能显著更高。
要点
- 钆布醇在除脑以外所有组织的信号增强幅度均高于钆特醇和钆特酸葡甲胺(P<0.05)。
- 三种对比剂的信号增强时间过程相似,且信号增强与组织钆浓度呈线性相关。
- 钆特醇与钆特酸葡甲胺的信号增强幅度无显著差异,组织钆浓度亦无差异。
关键影像表现/征象
- 信号增强的时间过程在三种对比剂的所有组织中均相似。
- 信号增强幅度呈组织依赖性,钆布醇在除脑以外的所有组织中均持续更高(P<0.05)。
- 钆特醇与钆特酸葡甲胺之间的信号增强幅度无显著差异。
- ICP-OES分析显示三种对比剂的组织钆浓度无差异。
- 三种对比剂的信号增强与相应组织钆浓度均呈线性相关。
诊断标准与关键数值
- 信号增强幅度:钆布醇在除脑以外所有组织中均高于钆特醇和钆特酸葡甲胺(P<0.05)。
- 单位钆浓度的信号增强效能:钆布醇显著更高。
- 钆特醇与钆特酸葡甲胺的信号增强幅度无显著差异。
- 三种对比剂的组织钆浓度无差异。
- 三种对比剂的信号增强与组织钆浓度均呈线性相关。
临床应用与阅片要点
- 在1.5 T T1加权MR成像中,钆布醇在脑以外组织产生的信号增强幅度高于钆特醇和钆特酸葡甲胺,阅片时需结合所用对比剂类型解读强化程度。
- 三种对比剂的信号增强时间过程相似,多期增强扫描的时相安排可依据增强动力学而非对比剂种类调整。
- 信号增强与组织钆浓度呈线性相关,提示强化程度可反映组织对比剂浓度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The signal enhancement (SE) and enhancement kinetics of gadolinium-based contrast agents (GBCAs) in T1-weighted magnetic resonance (MR) images depend on the relaxivity of the GBCA and its pharmacokinetic profile. This in vivo study systematically compared the SE (technical efficacy) and the enhancement kinetics of the 3 macrocyclic GBCAs gadobutrol, gadoteridol, and gadoterate meglumine in various body regions.
MATERIALS AND METHODS: A total of 15 healthy male white New Zealand rabbits were randomly divided into 3 groups (n = 5/group). The GBCAs were injected intravenously (0.1 mmol/kg body weight) and signal intensities from multiphase T1-weighted MR images (1.5 T; volumetric interpolated breath-hold examination (VIBE); repetition time/echo time/α: 4.74 milliseconds/2.38 milliseconds/10°) before and up to approximately 23 minutes after contrast injection were determined in the brain, tongue, submandibular gland, liver, spleen, prostate, muscle, and blood/aorta). Thirty minutes after injection, the animals were sacrificed and Gadolinium (Gd) concentrations were determined in the above-mentioned tissue samples by inductively coupled plasma optical emission spectrometry. Gadolinium tissue concentrations were correlated with the respective SE measurements in each tissue.
RESULTS: The time course of SE, representing the pharmacokinetic profile of the GBCA, was similar for all 3 agents in all tissues. The magnitude of SE was, however, tissue dependent and consistently higher for gadobutrol (P < 0.05 in all tissues but brain). No significant difference in the magnitude of SE was found between gadoteridol and gadoterate meglumine. The inductively coupled plasma optical emission spectrometry analysis revealed no differences in Gd-tissue concentrations between the GBCAs. A linear correlation was observed between SE and the respective Gd concentrations for all 3 GBCAs. A significantly higher enhancement efficacy, that is, SE per Gd concentration, was observed for gadobutrol.
CONCLUSIONS: Gadobutrol-enhanced MR imaging showed greater SE compared with gadoteridol and gadoterate meglumine, whereas the SE kinetics were similar among the 3 GBCAs. For all 3 GBCAs, the SE was independent of the body region.
引用
- Knobloch G, Frenzel T, Pietsch H, et al. Signal Enhancement and Enhancement Kinetics of Gadobutrol, Gadoteridol, and Gadoterate Meglumine in Various Body Regions: A Comparative Animal Study. Invest Radiol. 2020. PMID: 31985602. doi:10.1097/RLI.0000000000000645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。